1 row is stored for this page
| Field | Field type | Value |
|---|
| generic | String | |
| brand | String | Auvelity (dextromethorphan/bupropion ER) |
| structure | File | |
| classes | List of String, delimiter: , | NMDA receptor antagonist + sigma-1 agonist + NDRI (combination) |
| mechanism | String | |
| uses | String | Major depressive disorder in adults (FDA-approved August 2022) |
| starting_dose | String | 1 tablet (dextromethorphan 45 mg / bupropion 105 mg) PO daily × 3 days, then increase to 1 tablet BID |
| preparations | String | Dextromethorphan 45 mg + bupropion 105 mg ER tablets |
| fda_max | String | 2 tablets/day (dextromethorphan 90 mg / bupropion 210 mg) |
| pill_id | Text | |
| routes | List of String, delimiter: , | Oral |
| onset | String | Significant antidepressant response by week 1 in trials (faster than monoaminergic antidepressants which take 4-6 weeks) |
| duration | String | Sustained with twice-daily dosing |
| halflife | String | Dextromethorphan ~22 h (when CYP2D6 inhibited); bupropion ~21 h |
| bioavailability | String | Not formally characterized for the combination |
| pregnancy | String | Limited data; avoid |
| legal | String | Rx |
